Taiwan FDA registration 0056c33a7b8b57ae7f6fdb6bd0d99191
Baijie heme quality solution (unsterilized)
TW: 百捷血紅素品管液 (未滅菌)
Taiwan·Risk Class 1·Qinli Biotechnology Co., Ltd. New North Plant·Registered Apr 20, 2022 – Apr 20, 2027ActiveRegistration details
- Analysis ID
- 0056c33a7b8b57ae7f6fdb6bd0d99191
Company information
- Manufacturer
- Qinli Biotechnology Co., Ltd. New North Plant
- Manufacturer Country
- Taiwan, Province of China
- Authorized Representative
- GENERAL LIFE BIOTECHNOLOGY CO., LTD.
Product details
- Intended Use
- Limited to the classification and grading management of medical equipment, quality control materials (analytical and non-analytical) (A.1660) the first level identification range.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1660 Quality control materials (analytical and non-analytical)
- Import Information
- 國產;; QMS/QSD
Dates and status
- Registration Date
- Apr 20, 2022
- Expiry Date
- Apr 20, 2027
About this record
Access comprehensive regulatory information for Baijie heme quality solution (unsterilized) in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 1 medical device is registered under number 0056c33a7b8b57ae7f6fdb6bd0d99191 and manufactured by Qinli Biotechnology Co., Ltd. New North Plant. The authorized representative in Taiwan is GENERAL LIFE BIOTECHNOLOGY CO., LTD..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices